Radiation for bone metastases

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 3, 2011, Pages 227-232

  Bourgeois III, Daniel J ^a   Kraus, Stephen ^a,c   Maaloof, Bassam N ^b,c   Sartor, Oliver ^b,c  

^a Department of Radiation Oncology ^*  (United States)

^b Section of Hematology Oncology   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; Metastasis; Palliation; Radiation; Radiopharmaceuticals

Indexed keywords

ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

BONE TUMOR; HUMAN; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW;

BONE NEOPLASMS; DOSE FRACTIONATION; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE;

EID: 80052765975     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283499caa     Document Type: Review

References (47)

1. Justin UN. Radiotherapy for cancer pain management. Hematol Oncol Ann 1994; 2:432-442.
2. Cleland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330:592-596. (Pubitemid 24065792)
3. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system: an indolent disease. Am J Med 1986; 81:381-386. (Pubitemid 16003855)
4. Rose MD, Kagan AR. The final report of the expert panel for radiation oncology bone metastasis work group of the American College of Radiology. Int J Radiat Oncol Biol Phys 1998; 40:. (Pubitemid 28152927)
5. Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systemic review. J Clin Oncol 2007; 25:1423-1436. (Pubitemid 46706892)
6. Rasmusson B, Vejborg, Jensen AB, et al. Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year followup. Radiother Oncol 1995; 34:179-184.
7. Vargo M. Orthopedic management of malignant bone lesions. Radiother Oncol 1995; 34:179-184.
8. Arcangeli G, Giovinazzo G, Saracino B, et al. Radiation therapy in the management of symptomatic bone pain metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 1998; 42:1119-1126. (Pubitemid 29004157)
9. Fairchild A, Barnes E, Ghosh S, et al. International patterns of practice in palliative radiotherapy for painful bone metastases: evidence based practice? Int J Radiat Oncol Biol Phys 2009; 75:1501-1510.
10. Chow E, Lutz S, Beyene J. A single fraction for all, or an argument for fractionation tailored to fit the needs of each individual patient with bone metastases? Int J Radiat Oncol Biol Phys 2003; 55:565-567. (Pubitemid 36169996)
11. Cole DJ. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin Oncol 1989; 1:59-92.
12. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 1999; 52:111-121.
13. Price P, Hoskin PJ, Easton D, et al. Prospective randomized trial of single and multifraction radiotherapy schedule in the treatment of painful bony metastases. Radiother Oncol 1986; 6:247-255. (Pubitemid 16026730)
14. Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases. Cancer 1985; 55:1468-1477.
15. Sharma V, Gaye PM, Wahab SA, et al. Patterns of practice of palliative radiotherapy in Africa. Part 1: Bone and brain metastases. Int J Radiat Oncol Biol Phys 2008; 70:1195-1201. (Pubitemid 351308064)
16. Szumacher E, Llewellyn-Thomas H, Franssen E, et al. Treatment of bone metastases with palliative radiotherapy: patients' treatment preferences. Int J Radiat Oncol Biol Phys 2005; 61:1473-1481. (Pubitemid 40470431)
17. Wu JS, Kerba M, Wong RK, et al. Patterns of practice in palliative radiotherapy for painful bone metastases; impact of a regional access clinic on access to care. Int J Radiat Oncol Biol Phys 2010; 78:533-538. Excellent article on current practice patterns for radiotherapy.
18. Fitzpatrick P, Rider WD. Half-body radiotherapy of advanced cancer. J Can Assoc Radiol 1976; 27:75-79.
19. Salazar O, Sandhu T, da Motta N, et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 2001; 50:765-775. (Pubitemid 32519600)
20. Van der Linden Y, Lok J, Steenland E, et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch bone metastasis study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 2004; 59:528- 537. (Pubitemid 38622611)
21. Mithal NP, Needham PR, Hoskin PJ, et al. Retreatment with radiotherapy for painful bone metastases. Int J Radiat Oncol Biol Phys 1994; 29:1011-1014. (Pubitemid 24278968)
22. Jeremic B, Shibamoto Y, Igrutinovic I. Single 4 Gy re-irradiation for painful bone metastases following single fraction radiotherapy. Radiother Oncol 1999; 52:123-127. (Pubitemid 29461079)
23. Uppelschotten J, Wanders SL, de Jong JM. Single 4 Gy re-irradiation for painful bone metastasis following single fraction radiotherapy. Radiother Oncol 1995; 36:198-202.
24. Hird A, Chow E, Zhang L, et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three Canadian cancer centers. Int J Radiat Oncol Biol Phys 2009; 75:193-197.
25. Pompili A, Crispo F, Raus L, et al. Symptomatic spinal cord necrosis after irradiation for vertebral metastatic breast cancer. J Clin Oncol 2011; 29:53-56. Cautionary note on safety issues applicable to spinal cord radiation.
26. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97:798-804. (Pubitemid 40909122)
27. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010; 76:42-49. Reports of myelopathy from stereotactic radiosurgery are less than 1% when the maximum spinal cord dose is limited to 13 Gy in a single fraction or 20 Gy in three fractions but long-term data are insufficient to accurately calculate dose-volume relationships when the cord is treated with a hypofractionated regimen.
28. Delattre JY, Rosenblum MK, Thaler HT, et al. A model of radiation myelopathy in the rat: pathology, regional capillary permeability changes and treatment with dexamethazone. Brain 1988; 111:1319-1336. (Pubitemid 19028456)
29. Gibbs IC, Patil C, Gerszten PC, et al. Delayed radiation-induced myelopathy after spinal radiosurgery. Neurosurgery 2009; 64:67-72.
30. Gerszten PC, Ozhasoglu C, Burton SA, et al. Cyberknife frameless stereotactic spinal radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery 2004; 55:89-98. (Pubitemid 38859082)
31. Shiu AS, Chang EL, Ye JS, et al. Near simultaneous computed tomography image-guided stereotactic spinal radiotherapy: an emerging paradigm for achieving true stereotaxy. Int J Rad Oncol Biol Phys 2003; 57:605-613. (Pubitemid 37194285)
32. Luty S, Berk L, Change E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79:965-967. Outstanding review from the perspective of the American Society of Therapeutic Radiation Oncology.
33. Pecher P. Biological investigation with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. U Cal Public Pharmacol 1942; 2:117-149.
34. Hosain F, Spencer RP. Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background. Semin Nucl Med 1992; 22:11-16.
35. Blake GM, Zivanovic MA, McEwan AJ, et al. Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasizing osteosarcoma. Br J Radiol 1987; 60:253-259. (Pubitemid 17029103)
36. Blake GM, Gray JM, Zivanovic MA, et al. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis. Br J Radiol 1987; 60:685-692. (Pubitemid 17105137)
37. Dafermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001; 28:788-798. (Pubitemid 32662540)
38. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003; 44:519- 526. (Pubitemid 37328625)
39. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25:805-813. (Pubitemid 23123384)
40. Singh A, Holmes RA, Farhanghi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989; 30:1814- 1818.
41. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992; 33:1451- 1458.
42. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16:1574-1578.
43. Sartor O, Reid RH, Hoskin PJ, et al. Samarium- 153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63:940-945. (Pubitemid 38596683)
44. Sartor O, Bushnell D, Reid R, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007; 109:637-643. (Pubitemid 46190974)
45. Liepe K. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs 2009; 10:1346-1358.
46. A phase III study of alpharadin (Radium-223) in patients with symptomatic hormone refractory prostate cancer with skeletal metastases (ALSYMPCA) http://clinicaltrials.gov/ct2/show/NCT00699751 [Accessed 4 May 2011].
47. Alpharadin significantly improves overall survival in phase III trial in patients with castration-resistant prostate cancer that has spread to the bone http://www.press.bayer.com/baynews/baynews.nsf/id/Alpharadin-Significantly- Improves-Overall-Survival-Phase-III-Trial-Patients-Castration-Resistant?Open &ccm-001. [Accessed 14 June 2011].